{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:36:26Z","timestamp":1792791386978,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04325-y","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:14:15Z","timestamp":1770884055000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Rituximab for severe immune checkpoint inhibitor-related adverse events: a multicenter case series"],"prefix":"10.1007","volume":"75","author":[{"given":"St\u00e9phanie","family":"Hermabessiere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Jauzelon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Marmain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axelle","family":"Wauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philine","family":"Witkowski Durand Viel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Castille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Padern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouck","family":"Lamoureux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin Dominique","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Quantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre T. J.","family":"Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Coustal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"4325_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.898811","volume":"13","author":"P Ratanasrimetha","year":"2022","unstructured":"Ratanasrimetha P, Reddy VD, Kala J et al (2022) Case report: successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma. Front Immunol 13:898811. https:\/\/doi.org\/10.3389\/fimmu.2022.898811","journal-title":"Front Immunol"},{"issue":"12","key":"4325_CR2","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L et al (2022) Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33(12):1217\u20131238. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"issue":"36","key":"4325_CR3","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073\u20134086. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"issue":"2","key":"4325_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001287","volume":"8","author":"JS Lin","year":"2020","unstructured":"Lin JS, Wang DY, Mamlouk O et al (2020) Immune checkpoint inhibitor-associated reactivation of primary membranous nephropathy responsive to rituximab. J Immunother Cancer 8(2):e001287. https:\/\/doi.org\/10.1136\/jitc-2020-001287","journal-title":"J Immunother Cancer"},{"issue":"2","key":"4325_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.annonc.2020.12.001","volume":"32","author":"SN Deftereos","year":"2021","unstructured":"Deftereos SN, Georganikou D (2021) Effectiveness of rituximab in treating immune-checkpoint-inhibitor-induced immune-related adverse events: results of a systematic review. Ann Oncol 32(2):282\u2013283. https:\/\/doi.org\/10.1016\/j.annonc.2020.12.001","journal-title":"Ann Oncol"},{"issue":"5","key":"4325_CR6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25129","volume":"14","author":"V Jain","year":"2022","unstructured":"Jain V, Remley W, Bunag C et al (2022) Rituximab in refractory myositis and acute neuropathy secondary to checkpoint inhibitor therapy. Cureus 14(5):e25129. https:\/\/doi.org\/10.7759\/cureus.25129","journal-title":"Cureus"},{"issue":"11","key":"4325_CR7","doi-asserted-by":"publisher","first-page":"530","DOI":"10.14740\/jmc4008","volume":"13","author":"A Schwab","year":"2022","unstructured":"Schwab A, Assaad M, Hamadi R et al (2022) Pembrolizumab-induced myasthenia gravis and myositis: literature review on neurological toxicities of programmed death protein 1 inhibitors. J Med Cases 13(11):530\u2013535","journal-title":"J Med Cases"},{"issue":"30","key":"4325_CR8","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1200\/JCO.18.02141","volume":"37","author":"GS Phillips","year":"2019","unstructured":"Phillips GS, Wu J, Hellmann MD et al (2019) Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol 37(30):2746\u20132758. https:\/\/doi.org\/10.1200\/JCO.18.02141","journal-title":"J Clin Oncol"},{"key":"4325_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0214-9","volume":"5","author":"U Khan","year":"2017","unstructured":"Khan U, Ali F, Khurram MS et al (2017) Immunotherapy-associated autoimmune hemolytic anemia. J Immunother Cancer 5:15. https:\/\/doi.org\/10.1186\/s40425-017-0214-9","journal-title":"J Immunother Cancer"},{"issue":"2","key":"4325_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000750","volume":"8","author":"O Mamlouk","year":"2020","unstructured":"Mamlouk O, Lin JS, Abdelrahim M et al (2020) Checkpoint inhibitor-related renal vasculitis and use of rituximab. J Immunother Cancer 8(2):e000750. https:\/\/doi.org\/10.1136\/jitc-2020-000750","journal-title":"J Immunother Cancer"},{"issue":"9","key":"4325_CR11","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/annonc\/mdx252","volume":"28","author":"M Ito","year":"2017","unstructured":"Ito M, Fujiwara S, Fujimoto D et al (2017) Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient. Ann Oncol 28(9):2318\u20132319. https:\/\/doi.org\/10.1093\/annonc\/mdx252","journal-title":"Ann Oncol"},{"issue":"1","key":"4325_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/nyas.13562","volume":"1413","author":"M Marino","year":"2018","unstructured":"Marino M, Bartoccioni E, Alboini PE et al (2018) Rituximab in myasthenia gravis: a \u201cto be or not to be\u201d inhibitor of T cell function. Ann N Y Acad Sci 1413(1):41\u201348. https:\/\/doi.org\/10.1111\/nyas.13562","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"4325_CR13","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4049\/jimmunol.1400118","volume":"193","author":"A Palanichamy","year":"2014","unstructured":"Palanichamy A, Jahn S, Nickles D et al (2014) Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol 193(2):580\u2013586. https:\/\/doi.org\/10.4049\/jimmunol.1400118","journal-title":"J Immunol"},{"key":"4325_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2020.03.017","volume":"132","author":"D Maillet","year":"2020","unstructured":"Maillet D, Corbaux P, Stelmes JJ et al (2020) Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors. Eur J Cancer 132:61\u201370. https:\/\/doi.org\/10.1016\/j.ejca.2020.03.017","journal-title":"Eur J Cancer"},{"issue":"5","key":"4325_CR15","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","volume":"13","author":"JE Salem","year":"2023","unstructured":"Salem JE, Bretagne M, Abbar B et al (2023) Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov 13(5):1100\u20131115. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1180","journal-title":"Cancer Discov"},{"issue":"1","key":"4325_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s40425-019-0613-1","volume":"7","author":"W Damsky","year":"2019","unstructured":"Damsky W, Jilaveanu L, Turner N et al (2019) B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. J Immunother Cancer 7(1):153. https:\/\/doi.org\/10.1186\/s40425-019-0613-1","journal-title":"J Immunother Cancer"},{"key":"4325_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.733961","volume":"12","author":"LM Wulfken","year":"2021","unstructured":"Wulfken LM, Becker JC, Hayajneh R et al (2021) Case report: sustained remission due to PD-1-inhibition in a metastatic melanoma patient with depleted B cells. Front Immunol 12:733961. https:\/\/doi.org\/10.3389\/fimmu.2021.733961","journal-title":"Front Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04325-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04325-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04325-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:14:16Z","timestamp":1770884056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04325-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4325"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04325-y","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"7 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Montpellier University Hospital Ethics Committee (approval number 202100908). The requirement for informed consent was waived by the committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"76"}}